Opicapona y Perfiles de TratamIento en consultas de Trastornos del MOvimiento

Optimizar la detección de fibrilación atrial en el ataque isquémico transitorio

Outcomes of elective cancer surgery during the COVID-19 pandemic crisis: an international, multicentre, observational cohort study.

Outcomes of the spanish cohort of early access to pertuzumab and trastuzumab emtansine

Paper del bloqueig del múscul quadrat lumbar bilateral ecoguiat com a tècnica analgèsica en el dolor agut postoperatori en la cirurgia d’hemorroides i en el dolor crònic pèlvic perineal crònic

Percepció del paciente oncohematològico i cuidador principal del risc de caigudes. MÀSTER ICO BADALONA

Percepció dels pares sobre el mètode cangur realitzat a la UCI Neonatal.

Percepción del grado de seguridad de los pacientes hospitalizados en un hospital de la provincia de Girona de nivel 2B.

PeriOperative ISchemic Evaluation-3 (POISE-3) Trial. Ensayo Clínico que Evalúa la Isquemia Perioperatoria

Phase 3 Trial of Fianlimab (Regn3767, Anti-Lag-3) + Cemiplimab versus Pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic Melanoma

Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination.

Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy

PHASE II RANDOMIZED, CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ABTL0812 IN COMBINATION WITH FOLFIRINOX FOR FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER

Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE

phase III, randomized,open-label, multicenter study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer

Postgrau: Estudi sobre falsos positius en la detecció d’infeccions de tracte urinari (ITU) en mostres recollides amb bossa perineal en nens menors de 2 anys portadors de bolquer.l

PR‐30‐5017‐ PRIMA